{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:27:22Z","timestamp":1793244442819,"version":"4.5.0"},"reference-count":30,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Ultra-hypofractionated radiotherapy (uhRT) is increasingly used for low- and intermediate-risk localized prostate cancer, necessitating exceptional precision compared to conventional fractionation. CBCT-based online-adaptive uhRT may help mitigate pelvic organ motion but has not yet been established in clinical routine. We report initial clinical experiences focusing on the feasibility and technical aspects of treatment delivery. Materials and Methods: Seven patients (35 fractions) with low- or intermediate-risk prostate cancer were treated with online-adaptive uhRT on the Varian Ethos\u00ae system within routine clinical care. The target included the prostate and proximal seminal vesicles (CTV1, 5 \u00d7 7.25 Gy), with an integrated boost to the prostate (CTV2, 5 \u00d7 8.00 Gy). For each fraction, dose\u2013volume histogram (DVH) parameters for targets and organs at risk (OARs) were recorded retrospectively for both scheduled and adaptive plans, along with the plan selection decision. Plan quality was evaluated per clinical DVH constraints and target coverage. The treatment time was recorded. Results: Online-adaptive uhRT was successfully delivered every day in 5 patients and on alternate days in 2 patients. Mean treatment time was 30:17 (\u00b105:49 SD) minutes per fraction. The median recorded change in target and OAR volumes was &lt;10%. Adaptive plans resulted in a statistically significantly improved target coverage for CTV1 (V100%, p = 0.01), PTV1 (D98%, p &lt; 0.001), PTV2 boost (D98%, p &lt; 0.001) in Wilcoxon signed-rank tests. OAR dose reduction was limited, with a small improvement in bladder V40Gy (p = 0.02). Adaptive plans were applied in 32\/35 fractions (91.4%). To encompass intra-fractional motion in 95% of fractions, positional adjustments up to 0.77 cm (longitudinal), 0.37 cm (lateral), and 0.59 cm (sagittal) were required. Conclusions: Online-adaptive uhRT appears feasible, leading to optimized target volume coverage. Considerable treatment times must be taken into account. A second CBCT is recommended to compensate for intra-fractional motion. Further research regarding patient-related endpoints and cost-effectiveness is highly needed.<\/jats:p>","DOI":"10.3390\/medicina61101839","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:34:15Z","timestamp":1760452455000},"page":"1839","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CBCT-Based Online Adaptive, Ultra-Hypofractionated Radiotherapy for Prostate Cancer: First Clinical Experiences"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-9862","authenticated-orcid":false,"given":"Georg","family":"Wurschi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"},{"name":"Interdisciplinary Center for Clinical Research, Jena University Hospital, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Voigt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen","family":"Murr","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora","family":"Riede","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schwedas","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-4699","authenticated-orcid":false,"given":"Maximilian","family":"R\u00f6mer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Drozdz","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8085-8455","authenticated-orcid":false,"given":"Klaus","family":"Pietschmann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Jena University Hospital, 07747 Jena, Germany"},{"name":"Comprehensive Cancer Center Central Germany, Partner Site Jena, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103661","DOI":"10.1016\/j.critrevonc.2022.103661","article-title":"Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group","volume":"173","author":"Lapierre","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"Prostate Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wurschi, G.W., Graf, M., Weimann, S., M\u00e4urer, M., Straube, C., Medenwald, D., Domschikowski, J., M\u00fcnter, M., and Pietschmann, K. (2025). Travel costs and ecologic imprint associated with different fractionation schedules in prostate cancer radiotherapy. Das Gesundheitswesen.","DOI":"10.1055\/a-2512-9269"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"He, J., Wang, Q., Hu, Q., and Li, C. (2022). Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.841356"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10198-022-01467-5","article-title":"Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost-utility analysis alongside a randomized HYPO-RT-PC trial","volume":"24","author":"Sun","year":"2023","journal-title":"Eur. J. Health Econ."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13014-020-01681-6","article-title":"Strict bladder filling and rectal emptying during prostate SBRT: Does it make a dosimetric or clinical difference?","volume":"15","author":"Byun","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e230011","DOI":"10.1148\/rycan.230011","article-title":"Adaptive Radiation Therapy: A Review of CT-based Techniques","volume":"5","author":"Lavrova","year":"2023","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100662","DOI":"10.1016\/j.phro.2024.100662","article-title":"Comparison of online adaptive and non-adaptive magnetic resonance image-guided radiation therapy in prostate cancer using dose accumulation","volume":"32","author":"Murr","year":"2024","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/0284186X.2019.1627417","article-title":"First clinical experiences with a high field 1.5 T MR linac","volume":"58","author":"Bertelsen","year":"2019","journal-title":"Acta Oncol."},{"key":"ref_11","first-page":"54","article-title":"Adaptive radiotherapy: The Elekta Unity MR-linac concept","volume":"18","author":"Winkel","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","article-title":"1.5 T MR-guided and daily adapted SBRT for prostate cancer: Feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment","volume":"15","author":"Alongi","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phro.2019.02.002","article-title":"Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer","volume":"9","author":"Tetar","year":"2019","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.phro.2022.04.009","article-title":"Cone-beam computed tomography-guided online adaptive radiotherapy is feasible for prostate cancer patients","volume":"22","author":"Zwart","year":"2022","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acm2.13399","article-title":"Prospects for daily online adaptive radiotherapy via ethos for prostate cancer patients without nodal involvement using unedited CBCT auto-segmentation","volume":"22","author":"Moazzezi","year":"2021","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_16","first-page":"85","article-title":"MRI-guided adaptive radiotherapy for prostate cancer: When do we need to account for intra-fraction motion?","volume":"37","author":"Lawes","year":"2022","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/j.prro.2025.01.013","article-title":"Online Adaptive Five-Fraction Ablative Radiotherapy for Prostate Cancer Using a Conventional Linear Accelerator","volume":"15","author":"Jones","year":"2025","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/j.prro.2021.10.001","article-title":"Clinical Experience in Prostate Ultrahypofractionated Radiation Therapy With an Online Adaptive Method","volume":"12","year":"2022","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_19","first-page":"100693","article-title":"CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer","volume":"44","author":"Waters","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_20","first-page":"e64101","article-title":"Ultra-Hypofractionated Prostate Radiotherapy With Online Adaptive Technique: A Case Report","volume":"16","author":"Yoganathan","year":"2024","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110458","DOI":"10.1016\/j.radonc.2024.110458","article-title":"The added value of a new high-performance ring-gantry CBCT imaging system for prostate cancer patients","volume":"200","author":"Kunnen","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"147","author":"Altman","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"Griffin","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_25","unstructured":"JASP Team (2025). JASP, JASP Team. Version 0.19.3."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e13479","DOI":"10.1002\/acm2.13479","article-title":"Varian ethos online adaptive radiotherapy for prostate cancer: Early results of contouring accuracy, treatment plan quality, and treatment time","volume":"23","author":"Byrne","year":"2022","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e70074","DOI":"10.1002\/acm2.70074","article-title":"Quantification and dosimetric impact of intra-fractional bladder changes during CBCT-guided online adaptive radiotherapy for pelvic cancer treatments","volume":"26","author":"Buss","year":"2025","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Khouya, A., P\u00f6ttgen, C., Hoffmann, C., Ringbaek, T.P., L\u00fcbcke, W., Indenk\u00e4mpen, F., Guberina, M., Guberina, N., Gauler, T., and Stuschke, M. (2023). Adaptation Time as a Determinant of the Dosimetric Effectiveness of Online Adaptive Radiotherapy for Bladder Cancer. Cancers, 15.","DOI":"10.3390\/cancers15235629"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","first-page":"100771","article-title":"Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer\u2014Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial","volume":"46","author":"Fink","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1839\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T04:42:49Z","timestamp":1760589769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/10\/1839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["medicina61101839"],"URL":"https:\/\/doi.org\/10.3390\/medicina61101839","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}